F
F Fyhrquist
Researcher at Helsinki University Central Hospital
Publications - 11
Citations - 788
F Fyhrquist is an academic researcher from Helsinki University Central Hospital. The author has contributed to research in topics: Angiotensin-converting enzyme & Left ventricular hypertrophy. The author has an hindex of 8, co-authored 11 publications receiving 770 citations. Previous affiliations of F Fyhrquist include University of Helsinki.
Papers
More filters
Journal ArticleDOI
Reduction in Albuminuria Translates to Reduction in Cardiovascular Events in Hypertensive Patients. Losartan Intervention for Endpoint Reduction in Hypertension Study
Hans Ibsen,Michael H. Olsen,Kristian Wachtell,Knut Borch-Johnsen,Lars H Lindholm,Carl Erik Mogensen,Björn Dahlöf,Richard B. Devereux,Ulf de Faire,F Fyhrquist,Stevo Julius,Sverre E. Kjeldsen,Ole Lederballe-Pedersen,Markku S. Nieminen,Per Omvik,Suzanne Oparil,Ying Wan +16 more
TL;DR: Monitoring of albuminuria should be an integrated part of the management of hypertension if it is not decreased by the patient’s current antihypertensive and other treatment, and further intervention directed toward blood pressure control and other modifiable risks should be considered.
Journal ArticleDOI
Body Build and Risk of Cardiovascular Events in Hypertension and Left Ventricular Hypertrophy The LIFE (Losartan Intervention For Endpoint reduction in hypertension) Study
Giovanni de Simone,Kristian Wachtell,Kristian Wachtell,Vittorio Palmieri,Vittorio Palmieri,Darcy A. Hille,Gareth Beevers,Björn Dahlöf,Ulf de Faire,F Fyhrquist,Hans Ibsen,Stevo Julius,Sverre E. Kjeldsen,Sverre E. Kjeldsen,Ole Lederballe-Pedersen,Lars H Lindholm,Markku S. Nieminen,Per Omvik,Suzanne Oparil,Richard B. Devereux +19 more
TL;DR: Body build and risk of cardiovascular events in hypertension and left ventricular hypertrophy: the LIFE (Losartan Intervention For Endpoint reduction in hypertension) study as mentioned in this paper, which was conducted in the UK.
Journal Article
Regulation of angiotensin converting enzyme.
TL;DR: ACE biosynthesis may be enhanced by three categories of treatment: (1) glucocorticoid; (2) macrophage activation; (3) ACE inhibitors.
Journal ArticleDOI
Pulse pressure and effects of losartan or atenolol in patients with hypertension and left ventricular hypertrophy.
F Fyhrquist,Björn Dahlöf,Richard B. Devereux,Sverre E. Kjeldsen,Stevo Julius,Gareth Beevers,Ulf de Faire,Hans Ibsen,Krister Kristianson,Ole Lederballe-Pedersen,Lars H Lindholm,Markku S. Nieminen,Per Omvik,Suzanne Oparil,Darcy A. Hille,Paulette A. Lyle,Jonathan M. Edelman,Steven M. Snapinn,Hans Wedel +18 more
TL;DR: In patients with hypertension and left ventricular hypertrophy in the LIFE study, there were significantly higher risks, adjusted for the Framingham risk score, for the primary composite end point, stroke, and total mortality in the highest versus lowest quartile of pulse pressure with atenolol-based treatment.
Journal ArticleDOI
The Induction of Angiotensin Converting enzyme by Its Inhibitors
TL;DR: The inhibitors of angiotensin converting enzyme, captopril and enalapril, were found to increase ACE concentration in cultured human endothelial cells from cord artery as measured with a novel ACE assay employing MK 351A, an inhibitor of ACE, and with immunofluorescense labeling using anti-human lung ACE antibody.